Nektar Therapeutics (NKTR) Receivables (2010 - 2025)

Nektar Therapeutics' Receivables history runs 16 years deep, the most recent figure standing at $1.0 million for Q4 2025.

• In Q4 2025, Receivables fell 9.09% year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $1.0 million (down 9.09% YoY), while the FY2025 annual figure was $1.0 million, down 9.09% from the prior year.
• Receivables was $1.0 million for Q4 2025 at Nektar Therapeutics, up from $200000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $30.2 million in Q1 2022 to a low of $200000.0 in Q3 2025.
• Historically, Receivables has averaged $10.9 million across 5 years, with a median of $3.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Receivables tumbled 90.09% in 2023, then climbed 20.77% in 2024.
• A 5-year view of Receivables shows it stood at $23.9 million in 2021, then slumped by 72.04% to $6.7 million in 2022, then tumbled by 74.48% to $1.7 million in 2023, then tumbled by 35.48% to $1.1 million in 2024, then declined by 9.09% to $1.0 million in 2025.
• The last three Receivables figures came in at $1.0 million (Q4 2025), $200000.0 (Q3 2025), and $1.1 million (Q4 2024), per Business Quant data.